Smoking and IPMN malignant progression

R. A. Carr, A. M. Roch, K. Shaffer, S. Aboudi, C. M. Schmidt, J. DeWitt, E. P. Ceppa, M. G. House, N. J. Zyromski, A. Nakeeb, C. M. Schmidt

Research output: Contribution to journalArticle

5 Scopus citations


Background Patients with intraductal papillary mucinous neoplasm (IPMN) are at risk for invasive pancreatic cancer. We aim to characterize the impact of smoking on IPMN malignant progression. Methods Patients undergoing pancreatic resection for IPMN (1991–2015) were retrospectively reviewed using a prospectively collected database. Results Of 422 patients identified, 324 had complete data for analysis; 55% were smokers. Smoking status did not impact IPMN malignant progression (smokers/non-smokers: 22%/18% invasive grade; p = 0.5). Smokers were younger than non-smokers at the time of IPMN diagnosis (63 versus 68 years; p = 0.001). This association also held in the invasive IPMN subgroup (65 versus 72 years, p = 0.01). Despite this observation, rate of symptoms at diagnosis, cancer stage, and median survival were the same between smokers and non-smokers. Conclusion Although smoking is not associated with IPMN malignant progression, invasive IPMN is diagnosed at a younger age in smokers. These data suggest tobacco exposure may accelerate IPMN malignant progression.

Original languageEnglish (US)
Pages (from-to)494-497
Number of pages4
JournalAmerican Journal of Surgery
Issue number3
StatePublished - Mar 1 2017


  • Age
  • Intraductal papillary mucinous neoplasm (IPMN)
  • Smoking

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Smoking and IPMN malignant progression'. Together they form a unique fingerprint.

  • Cite this